pmid	doi	year	title	Hugo_Symbol
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	BRAF
33722842	10.1136/jclinpath-2020-207205	2022	Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung.	BRAF
33952592	10.1136/jclinpath-2021-207597	2022	Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.	BRAF
34015890	10.4143/crt.2021.218	2022	Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.	BRAF
34309914	10.1111/jcpt.13489	2022	Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.	BRAF
34687488	10.1002/gcc.23005	2022	Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.	BRAF
34704312	10.1111/cas.15176	2022	Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.	BRAF
34710243	10.1002/ajh.26390	2022	Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.	BRAF
34802044	10.1038/s41379-021-00954-z	2022	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.	BRAF
34843129	10.1111/his.14603	2022	ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.	BRAF
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	BRAF
35012520	10.1186/s12890-021-01803-0	2022	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.	BRAF
35064935	10.1111/his.14619	2022	Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis.	BRAF
35076701	10.1001/jamanetworkopen.2021.44923	2022	Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.	BRAF
35092381	10.31557/APJCP.2022.23.1.131	2022	Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.	BRAF
35147461	10.1177/00369330221078995	2022	Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.	BRAF
35189530	10.1016/j.ctarc.2022.100522	2022	Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.	BRAF
35205796	10.3390/cancers14041050	2022	Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders.	BRAF
35234079	10.1177/10668969221081432	2022	Hairy Cell Leukemia-Japanese Variant: Report of a Patient and Literature Review.	BRAF
35322197	10.1038/s41388-022-02266-1	2022	Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.	BRAF
35353542	10.1126/scitranslmed.abc7480	2022	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.	BRAF
35356636	10.14740/jh942	2022	Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.	BRAF
35359040	10.3760/cma.j.cn112151-20211220-00915	2022	[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].	BRAF
35363510	10.1200/JCO.21.02840	2022	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.	BRAF
35373885	10.1002/pbc.29575	2022	Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.	BRAF
35437610	10.1007/s00277-022-04795-x	2022	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.	BRAF
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BRAF
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	BRAF
35543076	10.1111/his.14680	2022	Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.	BRAF
35582532	10.20517/cdr.2021.85	2022	Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study.	BRAF
35663079	10.12998/wjcc.v10.i14.4541	2022	Bronchiolar adenoma with unusual presentation: Two case reports.	BRAF
35669427	10.3389/fonc.2022.873111	2022	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma.	BRAF
35739536	10.1186/s12920-022-01291-z	2022	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	BRAF
35748237	10.2217/pme-2021-0059	2022	Targeting molecular alterations in non-small-cell lung cancer: what's next?	BRAF
35774685	10.7759/cureus.25405	2022	A Rare Case of Metachronous Quadruple Primary Malignancies in a Single Patient: A Case Report and Comprehensive Literature Review.	BRAF
35789115	10.1111/his.14718	2022	Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia.	BRAF
35806042	10.3390/ijms23137037	2022	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.	BRAF
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	BRAF
35900506	10.4103/ijpm.ijpm_621_21	2022	Novel ALK-EML4 fusion with prominent mucous and hyaline stroma: Expanding the molecular genetic spectrum of S100 and CD34 positive spindle cell tumor.	BRAF
35900560	10.4103/jcrt.JCRT_559_20	2022	Primary pulmonary epithelial-myoepithelial carcinoma: Report of a rare and under-diagnosed low-grade malignancy.	BRAF
35980949	10.1371/journal.pone.0273207	2022	Various impacts of driver mutations on the PD-L1 expression of NSCLC.	BRAF
35984185	10.1097/MD.0000000000030094	2022	Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.	BRAF
35988454	10.1016/j.esmoop.2022.100560	2022	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.	BRAF
36051021	10.1002/jha2.486	2022	Lymphoma-associated acquired von Willebrand syndrome responsive to splenectomy: A case report.	BRAF
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	BRAF
32638211	10.1007/s12020-020-02411-4	2021	Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study.	BRAF
32815748	10.1080/0284186X.2020.1806358	2021	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.	BRAF
32915318	10.1007/s00262-020-02714-5	2021	Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.	BRAF
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	BRAF
32943371	10.1016/j.clml.2020.08.007	2021	Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.	BRAF
32954834	10.1080/17425247.2021.1825377	2021	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I.	BRAF
32969291	10.1080/10428194.2020.1824070	2021	The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification.	BRAF
32970929	10.1111/ajco.13449	2021	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.	BRAF
33068418	10.1093/neuonc/noaa233	2021	Population-based estimates of survival among elderly patients with brain metastases.	BRAF
33237469	10.1007/s00428-020-02971-w	2021	ALK alterations in salivary gland carcinomas.	BRAF
33360690	10.1016/j.jss.2020.11.012	2021	Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology.	BRAF
33387037	10.1007/s00432-020-03491-5	2021	Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.	BRAF
33506327	10.1007/s00428-021-03032-6	2021	Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases.	BRAF
33552685	10.1080/2162402X.2020.1865653	2021	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.	BRAF
33591844	10.1200/JCO.20.03570	2021	Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.	BRAF
33637515	10.1136/bcr-2021-241815	2021	Rare case of <i>BRAF V600E</i> mutant anaplastic pleomorphic xanthroastrocytoma in a 5-year survivor of acute lymphoblastic leukaemia.	BRAF
33650659	10.3892/or.2020.7911	2021	Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).	BRAF
33663128	10.1097/MD.0000000000024917	2021	BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.	BRAF
33671873	10.3390/cancers13040804	2021	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.	BRAF
33676171	10.1016/j.anndiagpath.2021.151720	2021	From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature.	BRAF
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	BRAF
33706747	10.1186/s12887-021-02590-7	2021	Giant congenital nodular melanoma in a newborn: a case report and literature review.	BRAF
33722699	10.1016/j.critrevonc.2021.103299	2021	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.	BRAF
33728131	10.7759/cureus.13112	2021	Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.	BRAF
33735913	10.1182/blood.2020010137	2021	A rapid genotyping panel for detection of primary central nervous system lymphoma.	BRAF
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	BRAF
33807876	10.3390/ijms22052625	2021	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.	BRAF
33811006	10.1016/j.clml.2021.02.005	2021	Inhibitor of BRAF<sup>V600E</sup> Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications.	BRAF
33833885	10.1155/2021/6680635	2021	A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis.	BRAF
33872472	10.1002/cncy.22434	2021	Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.	BRAF
33889528	10.21037/tlcr-20-1113	2021	A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations.	BRAF
33895683	10.1016/j.ejca.2021.03.026	2021	Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases.	BRAF
33898318	10.3389/fonc.2021.647598	2021	Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.	BRAF
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	BRAF
33979489	10.1056/NEJMoa2031298	2021	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.	BRAF
34009369	10.1210/clinem/dgab304	2021	Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.	BRAF
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	BRAF
34187757	10.1016/j.cllc.2021.05.006	2021	Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.	BRAF
34198843	10.3390/ijms22116099	2021	Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy.	BRAF
34275772	10.1016/j.clml.2021.06.007	2021	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.	BRAF
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	BRAF
34337566	10.1016/j.xcrm.2021.100350	2021	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.	BRAF
34343999	10.1159/000514821	2021	Multigene Combined Detection by RT-qPCR Using Cytological Specimens.	BRAF
34353680	10.1016/j.lungcan.2021.06.002	2021	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.	BRAF
34392186	10.1016/j.ejca.2021.06.043	2021	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.	BRAF
34466010	10.2147/CCID.S323865	2021	Reactive Langerhans Cell Proliferation Mimicking Langerhans Cell Histiocytosis in Association with Sézary Syndrome: A Case Report and Literature Review.	BRAF
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	BRAF
34593218	10.1016/j.bulcan.2021.06.009	2021	[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].	BRAF
34804000	10.3389/fimmu.2021.686057	2021	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.	BRAF
35116717	10.21037/tcr-21-1037	2021	Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.	BRAF
36045702	10.37349/etat.2021.00056	2021	A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?	BRAF
31439678	10.3324/haematol.2019.230375	2020	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.	BRAF
31598903	10.1007/s12094-019-02218-4	2020	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	BRAF
31715289	10.1016/j.pharmthera.2019.107438	2020	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.	BRAF
31747139	10.1002/cam4.2670	2020	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.	BRAF
31839532	10.1016/j.cllc.2019.11.006	2020	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.	BRAF
31917616	10.1080/17476348.2020.1714441	2020	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.	BRAF
31924734	10.1158/1078-0432.CCR-19-3443	2020	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).	BRAF
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	BRAF
31993771	10.1007/s00428-020-02752-5	2020	ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.	BRAF
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	BRAF
32037654	10.1002/pbc.28200	2020	Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib.	BRAF
32040482	10.1371/journal.pone.0227586	2020	Expression of the muscle-associated gene MYF6 in hairy cell leukemia.	BRAF
32045431	10.1371/journal.pone.0228188	2020	Precision medicine and actionable alterations in lung cancer: A single institution experience.	BRAF
32047535	10.1177/1758835919895756	2020	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.	BRAF
32052529	10.1111/pin.12909	2020	Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma.	BRAF
32066856	10.1038/s41598-020-59744-3	2020	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.	BRAF
32069373	10.1111/jcpt.13121	2020	Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update.	BRAF
32132106	10.1136/esmoopen-2019-000626	2020	Genomic-guided precision therapy for soft tissue sarcoma.	BRAF
32143579	10.1186/s12885-020-6681-2	2020	An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report.	BRAF
32186929	10.1080/14737140.2020.1744439	2020	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.	BRAF
32222087	10.1002/gcc.22844	2020	Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.	BRAF
32269611	10.3892/ol.2020.11460	2020	Emerging non-invasive detection methodologies for lung cancer.	BRAF
32283823	10.3390/ijms21072623	2020	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with <i>ALK</i> Rearrangement.	BRAF
32315234	10.1200/GO.20.00030	2020	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.	BRAF
32319330	10.1080/10428194.2020.1753045	2020	Detection of an IGH-<i>BRAF</i> fusion in a patient with BRAF Val600Glu negative hairy cell leukemia.	BRAF
32325863	10.3390/ijms21082847	2020	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition.	BRAF
32327174	10.1016/j.thorsurg.2020.01.004	2020	Molecular Targets Beyond the Big 3.	BRAF
32334988	10.1016/j.idc.2020.02.005	2020	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.	BRAF
32336065	10.3779/j.issn.1009-3419.2020.101.25	2020	[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].	BRAF
32365229	10.1002/cncr.32876	2020	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.	BRAF
32384767	10.3390/molecules25092174	2020	Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors.	BRAF
32402358	10.1016/j.ccm.2020.02.003	2020	Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.	BRAF
32427409	10.1002/gcc.22861	2020	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	BRAF
32429639	10.3779/j.issn.1009-3419.2020.101.04	2020	[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].	BRAF
32450593	10.1055/s-0039-3399564	2020	Molecular Diagnostics in Non-Small Cell Lung Carcinoma.	BRAF
32450595	10.1055/s-0039-1700994	2020	Targeted Therapy for Non-Small Cell Lung Cancer.	BRAF
32458259	10.1007/s11033-020-05509-0	2020	BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system.	BRAF
32521388	10.1016/j.lungcan.2020.05.018	2020	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.	BRAF
32608295	10.1080/10428194.2020.1783447	2020	Low-dose vemurafenib monotherapy in <i>BRAF<sup>V600E</sup></i> -mutated Erdheim-Chester disease.	BRAF
32627042	10.3892/or.2020.7612	2020	Proline‑rich polypeptide‑1 decreases cancer stem cell population by targeting BAFF chromatin‑remodeling complexes in human chondrosarcoma JJ012 cells.	BRAF
32650968	10.1016/j.patol.2019.11.004	2020	[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].	BRAF
32657049	10.1002/mgg3.1398	2020	Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua.	BRAF
32677947	10.1186/s12931-020-01437-6	2020	The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.	BRAF
32747568	10.1073/pnas.2005052117	2020	Activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.	BRAF
32756609	10.1371/journal.pone.0236580	2020	Molecular profiling of non-small cell lung cancer.	BRAF
32764384	10.3390/cancers12082182	2020	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.	BRAF
32804454	10.1097/PAS.0000000000001512	2020	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	BRAF
32821125	10.2147/OTT.S258365	2020	<i>SET-CAN</i> Fusion Gene in Acute Leukemia and Myeloid Neoplasms: Report of Three Cases and a Literature Review.	BRAF
32892557	10.3760/cma.j.cn112151-20200601-00430	2020	[Clinicopathological characteristics of indeterminate dendritic cell tumor of four cases].	BRAF
32907612	10.1186/s12943-020-01254-x	2020	Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.	BRAF
32980422	10.1016/j.humpath.2020.09.004	2020	Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.	BRAF
32988155	10.3760/cma.j.cn112152-20200323-00248	2020	[Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].	BRAF
32991441	10.1097/MD.0000000000022322	2020	First case of bronchiolar adenoma lined purely by mucinous luminal cells with molecular analysis: A case report.	BRAF
33043062	10.36469/jheor.2020.17088	2020	Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.	BRAF
33053222	10.1111/bjh.17055	2020	Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).	BRAF
33053439	10.1016/j.critrevonc.2020.103119	2020	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	BRAF
33053749	10.3390/cancers12102936	2020	The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.	BRAF
33079606	10.1200/GO.20.00265	2020	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.	BRAF
33101670	10.1016/j.amsu.2020.10.024	2020	Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.	BRAF
33162442	10.11406/rinketsu.61.1469	2020	[Marginal zone lymphoma-like primary bone marrow lymphoma with long-term pancytopenia preceding diagnosis].	BRAF
33269152	10.7759/cureus.11224	2020	Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.	BRAF
33297339	10.3390/nu12123755	2020	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.	BRAF
33327482	10.3390/cancers12123758	2020	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.	BRAF
33330555	10.3389/fmed.2020.594118	2020	Sarcoidosis and Cancer: A Complex Relationship.	BRAF
34589930	10.1016/j.jtocrr.2020.100023	2020	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.	BRAF
35117356	10.21037/tcr-20-1675	2020	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.	BRAF
30003317	10.1007/s00277-018-3425-3	2019	Langerhans cell histiocytosis associated with classical Hodgkin lymphoma contains BRAF V600E mutation.	BRAF
30048416	10.1097/LBR.0000000000000534	2019	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.	BRAF
30121320	10.1016/j.pharmthera.2018.08.007	2019	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.	BRAF
30279110	10.1016/j.cllc.2018.08.020	2019	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.	BRAF
30301660	10.1016/j.jgo.2018.09.008	2019	Treatment of older patients with advanced non-small cell lung cancer: A challenge.	BRAF
30320628	10.1097/PAS.0000000000001174	2019	An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.	BRAF
30322325	10.1080/10428194.2018.1519809	2019	Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.	BRAF
30526458	10.2174/1568009619666181210114559	2019	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.	BRAF
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	BRAF
30586141	10.1001/jamadermatol.2018.3662	2019	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.	BRAF
30611946	10.1016/j.wneu.2018.12.128	2019	The Radiological Imaging Features of Easily Misdiagnosed Epithelioid Glioblastoma in Seven Patients.	BRAF
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	BRAF
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	BRAF
30642913	10.1158/1078-0432.CCR-18-3904	2019	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.	BRAF
30653166	10.1097/MD.0000000000014180	2019	Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma: A case report.	BRAF
30677225	10.1002/smll.201805285	2019	Developing a New qPCR-Based System for Screening Mutation.	BRAF
30734348	10.1111/cup.13440	2019	A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma.	BRAF
30771009	10.1007/s11864-019-0618-5	2019	Current Treatment Options for Breast Cancer Brain Metastases.	BRAF
30775031	10.21037/jtd.2019.01.46	2019	Update on emerging biomarkers in lung cancer.	BRAF
30800314	10.1177/2050313X19830483	2019	Genetic and immunohistochemical analyses of ciliated muconodular papillary tumors of the lung: A report of five cases.	BRAF
30857967	10.1016/j.humpath.2019.03.002	2019	Fusion of ALK to the melanophilin gene MLPH in pediatric Spitz nevi.	BRAF
30865033	10.1097/MCP.0000000000000572	2019	Treatment of oncogene-driven non-small cell lung cancer.	BRAF
30869573	10.1089/thy.2018.0511	2019	Combination Treatment with the BRAF<sup>V600E</sup> Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma.	BRAF
30885850	10.1016/j.athoracsur.2019.02.010	2019	Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.	BRAF
30886831	10.3389/fonc.2019.00099	2019	Targeting Molecular Pathways in Intracranial Metastatic Disease.	BRAF
30902917	10.1634/theoncologist.2018-0572	2019	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.	BRAF
30914465	10.1634/theoncologist.2018-0112	2019	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.	BRAF
30917298	10.1177/0022034519837248	2019	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking.	BRAF
30937513	10.1007/s00292-019-0586-3	2019	[Bronchoalveolar lavage in hairy cell leukemia with pulmonary infiltration].	BRAF
30946933	10.1016/j.humpath.2019.03.004	2019	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.	BRAF
30975211	10.1186/s13046-019-1094-2	2019	Clinical development of targeted and immune based anti-cancer therapies.	BRAF
30982079	10.1007/s00018-019-03097-2	2019	Computational algorithms for in silico profiling of activating mutations in cancer.	BRAF
31016879	10.1002/cam4.2183	2019	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.	BRAF
31036508	10.1016/j.clml.2019.03.017	2019	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.	BRAF
31068044	10.1080/10428194.2019.1608536	2019	Hairy cell leukemia: present and future directions.	BRAF
31077558	10.1002/cyto.b.21785	2019	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.	BRAF
31151782	10.1016/j.cllc.2019.04.009	2019	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients.	BRAF
31172191	10.1093/ajcp/aqz056	2019	Histiocytic Sarcoma Following B-Lymphoblastic Leukemia/Lymphoma.	BRAF
31187521	10.1002/hon.2594	2019	New treatment options in hairy cell leukemia with focus on BRAF inhibitors.	BRAF
31202602	10.1016/j.rmr.2019.04.003	2019	[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].	BRAF
31229894	10.1016/j.isci.2019.06.001	2019	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.	BRAF
31242043	10.1200/CCI.19.00002	2019	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.	BRAF
31257073	10.1016/j.ccell.2019.05.015	2019	RAC1<sup>P29S</sup> Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.	BRAF
31280902	10.1016/j.cvsm.2019.05.002	2019	Novel Noninvasive Diagnostics.	BRAF
31281144	10.11406/rinketsu.60.559	2019	[Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration].	BRAF
31297240	10.1136/esmoopen-2019-000498	2019	Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.	BRAF
31317311	10.1007/s00428-019-02608-7	2019	Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.	BRAF
31354304	10.2147/OTT.S202061	2019	<i>BRAF</i> V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.	BRAF
31412611	10.3390/ijms20163939	2019	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (<i>ALK</i>) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.	BRAF
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	BRAF
31443309	10.3390/medicina55080490	2019	Malignant Pleural Effusion and Its Current Management: A Review.	BRAF
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	BRAF
31447330	10.1016/j.lpm.2019.07.026	2019	[Hairy cell leukemia].	BRAF
31538423	10.3349/ymj.2019.60.10.890	2019	Hairiness is a Facsimile of Reorganized Cytoskeletons: A Cytopathic Effect of <i>Coxiella burnetii</i>.	BRAF
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	BRAF
31591741	10.1002/ajh.25653	2019	Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.	BRAF
31711449	10.1186/s12890-019-0964-x	2019	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.	BRAF
31737634	10.3389/fmed.2019.00233	2019	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.	BRAF
31768065	10.1038/s41591-019-0653-6	2019	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.	BRAF
31819518	10.2147/OTT.S230309	2019	Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.	BRAF
32010591	10.21037/tlcr.2019.12.24	2019	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.	BRAF
28280984	10.1007/s00595-017-1497-7	2018	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.	BRAF
28544061	10.1111/imj.13491	2018	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.	BRAF
28756651	10.1111/crj.12670	2018	Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.	BRAF
28975389	10.1007/s00277-017-3145-0	2018	PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma.	BRAF
29046324	10.1530/EJE-17-0499	2018	<i>ETV6-NTRK3</i> and <i>STRN-ALK</i> kinase fusions are recurrent events in papillary thyroid cancer of adult population.	BRAF
29129559	10.1016/j.clcc.2017.10.006	2018	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.	BRAF
29134959	10.1038/nrclinonc.2017.175	2018	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.	BRAF
29165687	10.1093/jnci/djx209	2018	Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.	BRAF
29198034	10.1007/s00428-017-2268-y	2018	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.	BRAF
29361134	10.1093/annonc/mdx631	2018	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.	BRAF
29364576	10.1002/cncy.21963	2018	Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay.	BRAF
29398453	10.1016/j.jmoldx.2017.11.004	2018	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.	BRAF
29439113	10.1136/gutjnl-2016-312608	2018	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.	BRAF
29507487	10.3747/co.25.3867	2018	Standardizing biomarker testing for Canadian patients with advanced lung cancer.	BRAF
29516752	10.1080/13696998.2018.1450261	2018	Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.	BRAF
29556019	10.1038/s41375-018-0082-4	2018	High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.	BRAF
29565494	10.26355/eurrev_201803_14479	2018	Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion.	BRAF
29588308	10.1158/1078-0432.CCR-18-0103	2018	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.	BRAF
29600072	10.21037/jtd.2017.12.68	2018	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.	BRAF
29618685	10.11406/rinketsu.59.281	2018	[Splenic diffuse red pulp small B-cell lymphoma diagnosed by splenectomy initially mimicking hairy cell leukemia-Japanese variant].	BRAF
29631966	10.1016/j.cllc.2018.03.010	2018	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.	BRAF
29633575	10.1002/cjp2.102	2018	Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.	BRAF
29654269	10.1038/s41375-018-0108-y	2018	Kinase domain activation through gene rearrangement in multiple myeloma.	BRAF
29666969	10.1007/s10014-018-0316-1	2018	Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia.	BRAF
29702524	10.1097/MOH.0000000000000435	2018	Genetic convergence of rare lymphomas.	BRAF
29708356	10.14735/amko2018130	2018	MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.	BRAF
29764505	10.1186/s40880-018-0284-1	2018	Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.	BRAF
29807803	10.1016/j.clml.2018.05.008	2018	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.	BRAF
29846633	10.1210/jc.2017-01845	2018	Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.	BRAF
29854308	10.18632/oncotarget.25209	2018	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.	BRAF
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	BRAF
29881714	10.3389/fonc.2018.00161	2018	Mechanisms and Therapy for Cancer Metastasis to the Brain.	BRAF
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	BRAF
29911108	10.21037/atm.2018.05.02	2018	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.	BRAF
29920315	10.1016/j.jaad.2018.06.018	2018	Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions.	BRAF
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	BRAF
29992751	10.1002/cam4.1667	2018	Emerging findings into molecular mechanism of brain metastasis.	BRAF
30035752	10.1097/DAD.0000000000001072	2018	Langerhans Cell Histiocytosis Associated With Underlying Hematolymphoid Disorders in Adults: Report of 2 Cases and Review of the Literature.	BRAF
30089719	10.1172/jci.insight.120858	2018	Personalized therapy for lung cancer: striking a moving target.	BRAF
30092236	10.1016/j.humpath.2018.07.029	2018	So-called non-classic ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors.	BRAF
30121602	10.1136/bmjopen-2018-021642	2018	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.	BRAF
30172272	10.3779/j.issn.1009-3419.2018.08.10	2018	[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].	BRAF
30188361	10.1097/PAP.0000000000000206	2018	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.	BRAF
30198802	10.1080/14737140.2018.1521272	2018	Dabrafenib and trametinib for the treatment of non-small cell lung cancer.	BRAF
30228211	10.1136/jclinpath-2018-205396	2018	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.	BRAF
30231382	10.1200/EDBK_201331	2018	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.	BRAF
30290811	10.1186/s12943-018-0886-x	2018	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.	BRAF
30334450	10.4149/neo_2018_171225N843	2018	PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.	BRAF
30335863	10.1371/journal.pone.0206014	2018	Oncogenic mutations in IKKβ function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation.	BRAF
30354850	10.1177/1753466618808660	2018	Biomarkers in the diagnosis of pleural diseases: a 2018 update.	BRAF
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	BRAF
30474563	10.1186/s13000-018-0772-2	2018	Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature.	BRAF
30504104		2018	Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.	BRAF
30536772	10.1111/bpa.12666	2018	A 72-year old female with multiple supra- and infratentorial dural masses.	BRAF
30546443	10.3892/ol.2018.9560	2018	ALK expression favorably impacts the prognosis of <i>NRAS</i>-mutated metastatic melanomas.	BRAF
30622805	10.21037/jtd.2018.08.14	2018	Therapeutic bronchoscopy in the era of genotype directed lung cancer management.	BRAF
30680072	10.18632/oncotarget.26428	2018	Targeted therapies for advanced non-small cell lung cancer.	BRAF
25901525	10.2174/1389450116666150330114441	2017	Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?	BRAF
26882062	10.1097/IOP.0000000000000661	2017	Comparative Study of Clinical, Pathological, Radiological, and Genetic Features of Patients With Adult Ocular Adnexal Xanthogranulomatous Disease, Erdheim-Chester Disease, and IgG4-Related Disease of the Orbit/Ocular Adnexa.	BRAF
27347751	10.1080/10428194.2016.1196813	2017	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.	BRAF
27545333	10.1080/10428194.2016.1213830	2017	BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.	BRAF
27575422	10.1016/j.jtho.2016.08.137	2017	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.	BRAF
27776007	10.1097/PAS.0000000000000761	2017	A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.	BRAF
27910030	10.1007/978-1-4939-6703-2_22	2017	Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.	BRAF
27912827	10.1016/j.hoc.2016.08.010	2017	New Targets in Non-Small Cell Lung Cancer.	BRAF
27980230	10.18632/oncotarget.13936	2017	A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.	BRAF
28084334	10.1038/modpathol.2016.235	2017	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.	BRAF
28088073	10.1016/j.ctrv.2016.12.005	2017	Strategies to design clinical studies to identify predictive biomarkers in cancer research.	BRAF
28088512	10.1016/j.jtho.2017.01.004	2017	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.	BRAF
28150468	10.1111/pin.12512	2017	Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: Case report and review of the literature.	BRAF
28194436	10.1172/jci.insight.89473	2017	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.	BRAF
28203297	10.1177/1758834016670555	2017	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.	BRAF
28212996	10.1016/j.lungcan.2016.12.005	2017	Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).	BRAF
28218040	10.1177/1010428317691413	2017	Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using single-molecule amplification and re-sequencing technology.	BRAF
28237660	10.1016/j.yexmp.2017.02.014	2017	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.	BRAF
28246485	10.3748/wjg.v23.i6.1106	2017	Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.	BRAF
28280620	10.21037/jgo.2017.01.14	2017	Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.	BRAF
28297625	10.1200/JCO.2016.71.1556	2017	Genomics of Hairy Cell Leukemia.	BRAF
28351340	10.1089/thy.2016.0254	2017	Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.	BRAF
28376906	10.1186/s13256-017-1253-z	2017	BRAF <sup>V600E</sup> expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report.	BRAF
28399347	10.22608/APO.201710	2017	Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes--The 2017 J. Donald M. Gass Lecture.	BRAF
28433076	10.1016/j.jmoldx.2016.11.005	2017	Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.	BRAF
28487464	10.1634/theoncologist.2016-0458	2017	Targeting <i>BRAF</i>-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.	BRAF
28507204	10.1634/theoncologist.2016-0376	2017	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.	BRAF
28550959	10.1016/j.cllc.2017.04.006	2017	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.	BRAF
28592763	10.11406/rinketsu.58.480	2017	Malignant lymphoma: pathophysiology and current therapy.	BRAF
28608966	10.1002/cncr.30794	2017	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.	BRAF
28609002	10.1002/cncy.21866	2017	Analytic inquiry: Molecular testing in lung cancer.	BRAF
28762087	10.1007/s11523-017-0520-7	2017	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).	BRAF
28840016	10.21037/jtd.2017.06.20	2017	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.	BRAF
28880462	10.1111/cup.13017	2017	Indeterminate dendritic cell neoplasm of the skin: A 2-case report and review of the literature.	BRAF
28883003	10.1158/0008-5472.CAN-16-2691	2017	Discovery of Human-Similar Gene Fusions in Canine Cancers.	BRAF
28892161	10.1002/path.4982	2017	A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.	BRAF
28976960	10.1038/nature24037	2017	Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.	BRAF
29068003	10.1038/nrc.2017.84	2017	Understanding and targeting resistance mechanisms in NSCLC.	BRAF
29110361	10.1002/ajh.24936	2017	Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.	BRAF
29167001	10.3779/j.issn.1009-3419.2017.11.02	2017	[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].	BRAF
29370427	10.1093/jnci/djx089	2017	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.	BRAF
29872694	10.1038/s41698-017-0009-y	2017	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.	BRAF
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	BRAF
26566875	10.1158/2159-8290.CD-15-0913	2016	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	BRAF
26618563	10.1586/14737140.2016.1126514	2016	Emerging targeted therapies in non-small cell lung cancer.	BRAF
26620497	10.1177/1753465815617871	2016	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.	BRAF
26646246	10.1007/s00432-015-2081-4	2016	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.	BRAF
26668120	10.1038/nrendo.2015.217	2016	Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.	BRAF
26695526	10.1002/cncr.29812	2016	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.	BRAF
26703797	10.1007/978-3-319-24932-2_2	2016	Emerging Biomarkers in Personalized Therapy of Lung Cancer.	BRAF
26711128	10.1007/s00595-015-1295-z	2016	Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.	BRAF
26720421	10.1001/jamaoncol.2015.4482	2016	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.	BRAF
26777916	10.1016/S0140-6736(16)00004-0	2016	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	BRAF
26800678	10.1007/s00108-015-0006-6	2016	[Classification of malignant lymphomas. Current situation].	BRAF
26845116	10.1016/j.jtho.2015.10.005	2016	Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.	BRAF
26855057	10.1016/j.ejmg.2016.01.003	2016	Acute lymphoblastic leukemia in the context of RASopathies.	BRAF
26857243	10.1186/s13000-016-0458-6	2016	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.	BRAF
26868143	10.1007/s00428-015-1881-x	2016	CD27-positive hairy cell leukemia-Japanese variant.	BRAF
26872010	10.1097/PAS.0000000000000611	2016	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.	BRAF
26873340	10.1177/1066896916630375	2016	Spitz Tumors: Comparison of Histological Features in Relationship to Immunohistochemical Staining for ALK and NTRK1.	BRAF
26893860	10.3892/mco.2015.690	2016	Genetic alterations in lung adenocarcinoma with a micropapillary component.	BRAF
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	BRAF
26925962	10.1038/nrclinonc.2016.19	2016	Evolving molecularly targeted therapies for advanced-stage thyroid cancers.	BRAF
26941398	10.1182/blood-2015-11-680074	2016	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.	BRAF
26964771	10.1016/j.jtho.2016.02.018	2016	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.	BRAF
26968843	10.1186/s12885-016-2249-6	2016	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.	BRAF
27033383	10.3760/cma.j.issn.0529-5807.2016.04.002	2016	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].	BRAF
27034005	10.18632/oncotarget.8427	2016	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.	BRAF
27070758	10.1016/j.leukres.2016.03.002	2016	Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.	BRAF
27073482	10.3892/ol.2016.4235	2016	<i>EGFR</i>, <i>ALK</i>, <i>RET</i>, <i>KRAS</i> and <i>BRAF</i> alterations in never-smokers with non-small cell lung cancer.	BRAF
27080983	10.1038/modpathol.2016.66	2016	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.	BRAF
27099101	10.1111/resp.12737	2016	Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.	BRAF
27101528	10.1097/MOH.0000000000000256	2016	Histiocytic neoplasms in the era of personalized genomic medicine.	BRAF
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	BRAF
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	BRAF
27126828	10.2146/ajhp150863	2016	Specialty pharmacy services for patients receiving oral medications for solid tumors.	BRAF
27135738	10.1038/nm.4092	2016	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	BRAF
27149123		2016	Flavopiridol Induces Apoptosis via Mitochondrial Pathway in B16F10 Murine Melanoma Cells and a Subcutaneous Melanoma Tumor Model.	BRAF
27200298	10.3389/fonc.2016.00112	2016	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.	BRAF
27249714	10.1200/EDBK_100006	2016	Targeted Therapy in Brain Metastases: Ready for Primetime?	BRAF
27262212	10.1016/j.jtho.2016.04.033	2016	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.	BRAF
27266901	10.1016/j.rmr.2016.01.007	2016	[Molecular epidemiology of the lung cancer].	BRAF
27275640		2016	[Novelties in the diagnostics and therapy of hairy cell leukemia].	BRAF
27298405	10.1200/JCO.2016.67.2410	2016	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.	BRAF
27343444	10.1016/j.jtho.2016.06.001	2016	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.	BRAF
27409166	10.18632/oncotarget.10464	2016	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.	BRAF
27535394	10.1007/978-3-319-40389-2_8	2016	Targeted Therapies for Lung Cancer.	BRAF
27600764	10.1038/ncomms12602	2016	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	BRAF
27614521	10.1016/j.canrad.2016.07.082	2016	[Radiotherapy and targeted therapy/immunotherapy].	BRAF
27615396	10.1016/j.jtho.2016.08.142	2016	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.	BRAF
27659822	10.1007/s00381-016-3163-6	2016	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.	BRAF
27672108	10.1093/annonc/mdw282	2016	First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.	BRAF
27696251	10.1007/s12020-016-1080-9	2016	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.	BRAF
27732995	10.1055/s-0036-1592111	2016	Metastatic Lung Cancer: Emerging Therapeutic Strategies.	BRAF
27769042	10.18632/oncotarget.12705	2016	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.	BRAF
27775641	10.3390/ijms17101759	2016	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.	BRAF
27889782	10.1159/000453085	2016	Molecular Pathology: A Requirement for Precision Medicine in Cancer.	BRAF
30363424	10.1002/mdc3.12277	2016	Neurohistiocytosis of the Cerebellum: A Rare Cause of Ataxia.	BRAF
25029639	10.3109/10428194.2014.939966	2015	Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.	BRAF
25242093	10.3109/10428194.2014.946028	2015	BRAF V600E mutation-specific immunohistochemistry is a rare finding in dendritic cell- and histiocyte-derived tumors.	BRAF
25273224	10.1002/cncr.29042	2015	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.	BRAF
25357018	10.1097/DAD.0000000000000231	2015	Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.	BRAF
25423572	10.1210/jc.2014-3250	2015	Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases.	BRAF
25468140	10.1016/j.metabol.2014.10.027	2015	Biomarkers for personalized oncology: recent advances and future challenges.	BRAF
25480661	10.1182/blood-2014-10-603100	2015	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.	BRAF
25485910	10.1038/nm.3751	2015	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.	BRAF
25501013	10.1097/PAS.0000000000000368	2015	A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.	BRAF
25511147	10.1309/AJCPDN4Q1JTFGCFC	2015	Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.	BRAF
25511150	10.1309/AJCPQLQ89VXTVWKN	2015	The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia.	BRAF
25527510	10.1530/ERC-14-0467	2015	Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.	BRAF
25563425	10.3109/10428194.2014.1001988	2015	Novel therapeutic options for relapsed hairy cell leukemia.	BRAF
25587943	10.1080/15592294.2014.1003746	2015	Epigenetic regulation in human melanoma: past and future.	BRAF
25602801	10.1097/PAS.0000000000000387	2015	Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.	BRAF
25629635	10.1097/JTO.0000000000000487	2015	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	BRAF
25657019	10.1183/09031936.00097214	2015	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.	BRAF
25673595	10.4103/0377-4929.151190	2015	V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia.	BRAF
25675010	10.1097/PAS.0000000000000376	2015	Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome.	BRAF
25689095	10.1111/resp.12490	2015	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	BRAF
25704901	10.1016/j.rmr.2014.08.014	2015	[Targeted therapies in non-small cell lung cancer in 2014].	BRAF
25729732	10.3343/alm.2015.35.2.257	2015	BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases.	BRAF
25735315	10.1093/annonc/mdv136	2015	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).	BRAF
25738220	10.1097/JTO.0000000000000516	2015	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	BRAF
25745045	10.1183/09031936.00097314	2015	No impact of passive smoke on the somatic profile of lung cancers in never-smokers.	BRAF
25758902	10.1007/s40291-015-0133-8	2015	Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.	BRAF
25758903	10.1111/bjh.13291	2015	BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients.	BRAF
25787243	10.1016/j.anndiagpath.2015.02.008	2015	Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma.	BRAF
25807485	10.1038/nature14336	2015	Therapy-induced tumour secretomes promote resistance and tumour progression.	BRAF
25809821	10.1111/his.12694	2015	Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma.	BRAF
25823918	10.1016/j.clinthera.2015.02.018	2015	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	BRAF
25842168	10.1016/j.ctrv.2015.03.009	2015	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.	BRAF
25843629	10.1016/j.cell.2015.02.043	2015	The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.	BRAF
25858127	10.1684/abc.2015.1037	2015	[Chronic B-cell lymphoproliferative disorders with hairy cells].	BRAF
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	BRAF
25925381	10.1016/j.neo.2015.03.004	2015	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.	BRAF
25926053	10.1038/ncomms8002	2015	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.	BRAF
25960206	10.1002/gcc.22253	2015	NFkB is activated by multiple mechanisms in hairy cell leukemia.	BRAF
25989738	10.1007/s00115-015-4278-9	2015	[Therapeutic options for brain metastases].	BRAF
25995428	10.6004/jnccn.2015.0201	2015	Targeted/emerging therapies for metastatic non-small cell lung cancer.	BRAF
26011488	10.1038/nrclinonc.2015.92	2015	Adolescent and young adult patients with cancer: a milieu of unique features.	BRAF
26028064	10.7314/apjcp.2015.16.10.4147	2015	Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.	BRAF
26047060	10.1080/15384047.2015.1057359	2015	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.	BRAF
26058013	10.3390/md13063625	2015	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.	BRAF
26071465	10.1309/AJCP5WVXJ2KTLODO	2015	Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.	BRAF
26109403	10.1111/bjd.13958	2015	Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.	BRAF
26113587	10.1136/bcr-2015-209343	2015	Hodgkin's lymphoma in an adolescent previously treated with surgical resection of third ventricular juvenile pilocytic astrocytoma.	BRAF
26149886	10.1016/S1470-2045(15)00077-7	2015	Genomic alterations in lung adenocarcinoma.	BRAF
26154707	10.1097/CCO.0000000000000214	2015	New insights in the management of patients with hairy cell leukemia.	BRAF
26215190	10.1245/s10434-015-4704-z	2015	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.	BRAF
26235020	10.3171/2015.5.FOCUS15143	2015	The genetic basis of intradural spinal tumors and its impact on clinical treatment.	BRAF
26281695		2015	[Molecular target therapies for skin cancers].	BRAF
26339365		2015	Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.	BRAF
26345285	10.1186/s12885-015-1639-5	2015	A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.	BRAF
26350141	10.1016/j.leukres.2015.08.017	2015	BRAF<sup>V600E</sup> induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.	BRAF
26358176	10.1038/cgt.2015.39	2015	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	BRAF
26371045	10.3390/cancers7030864	2015	The Evolution of Therapies in Non-Small Cell Lung Cancer.	BRAF
26373952	10.1186/s13000-015-0409-7	2015	Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.	BRAF
26422542		2015	NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.	BRAF
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	BRAF
26579470	10.1016/j.apsb.2015.07.001	2015	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	BRAF
26581482	10.1186/s13104-015-1675-x	2015	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.	BRAF
26614896	10.1016/j.beha.2015.10.017	2015	Clinical features and diagnosis of hairy cell leukemia.	BRAF
26614898	10.1016/j.beha.2015.10.019	2015	Bone marrow and splenic histology in hairy cell leukaemia.	BRAF
26615134	10.1053/j.seminoncol.2015.09.028	2015	Overcoming Resistance to Targeted Therapies in Cancer.	BRAF
26688666	10.4137/BIC.S29326	2015	Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.	BRAF
26826484	10.1016/S0003-4266(16)30009-9	2015	Molecular perspectives in differentiated thyroid cancer.	BRAF
26887510		2015	[Detection and significance of BRAF gene in mature T/NK cell lymphoma].	BRAF
23988776	10.1183/09031936.00018013	2014	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.	BRAF
24296758	10.1158/1541-7786.MCR-13-0479-T	2014	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.	BRAF
24297085	10.1093/annonc/mdt495	2014	Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.	BRAF
24346091	10.1097/JTO.0000000000000024	2014	Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer.	BRAF
24354593	10.1517/14728214.2014.873403	2014	Emerging protein kinase inhibitors for non-small cell lung cancer.	BRAF
24380695	10.1016/j.lungcan.2013.11.019	2014	On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.	BRAF
24397598	10.3109/10428194.2013.878461	2014	Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma.	BRAF
24420742	10.1007/s00428-014-1535-4	2014	Prognostic and predictive biomarkers in lung cancer. A review.	BRAF
24423920	10.1038/bjc.2013.794	2014	Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.	BRAF
24433452	10.1111/bjh.12735	2014	Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.	BRAF
24445188	10.1016/j.clml.2013.12.003	2014	BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.	BRAF
24471909	10.3109/10428194.2014.887713	2014	Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.	BRAF
24481316	10.1097/JTO.0b013e3182a406d1	2014	Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.	BRAF
24503701	10.1371/journal.pone.0087456	2014	Immunohistochemistry for myc predicts survival in colorectal cancer.	BRAF
24531447	10.1038/bcj.2014.3	2014	Hairy cell leukemia: short review, today's recommendations and outlook.	BRAF
24548766	10.1016/j.ejca.2014.01.018	2014	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	BRAF
24552757	10.1016/j.lungcan.2014.01.023	2014	BRAF-mutations in non-small cell lung cancer.	BRAF
24629636	10.1016/j.lungcan.2014.02.007	2014	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.	BRAF
24633422	10.1007/s00268-014-2485-3	2014	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.	BRAF
24659662		2014	Capsaicin induced apoptosis and gene expression dysregulation of human acute lymphoblastic leukemia CCRF-CEM cells.	BRAF
24689848	10.1111/cas.12408	2014	Disease-specific mutations in mature lymphoid neoplasms: recent advances.	BRAF
24691006	10.1371/journal.pone.0092147	2014	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.	BRAF
24699316	10.1371/journal.pone.0092820	2014	High fidelity copy number analysis of formalin-fixed and paraffin-embedded tissues using Affymetrix Cytoscan HD chip.	BRAF
24700479	10.1002/cncr.28604	2014	Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.	BRAF
24727987	10.1159/000355902	2014	Successes and limitations of targeted cancer therapy in lung cancer.	BRAF
24729716	10.2147/OTT.S60122	2014	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.	BRAF
24789721	10.1007/s12253-014-9783-9	2014	Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.	BRAF
24857124	10.14694/EdBook_AM.2014.34.e353	2014	Management and future directions in non-small cell lung cancer with known activating mutations.	BRAF
24878193	10.1016/j.bmcl.2014.05.030	2014	Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.	BRAF
24920406	10.3892/ijo.2014.2491	2014	Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).	BRAF
24994538	10.1007/s00277-014-2140-y	2014	Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.	BRAF
24997557	10.1016/j.clml.2014.06.004	2014	Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.	BRAF
25053603	10.1016/j.canrad.2014.05.007	2014	[Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].	BRAF
25066006	10.1111/his.12515	2014	Multifocal synchronous mucinous adenocarcinomas arising in congenital pulmonary airway malformation: a case report with molecular study.	BRAF
25120816		2014	Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.	BRAF
25126481	10.1089/biores.2014.0011	2014	Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene.	BRAF
25133005	10.1155/2014/497027	2014	Primary hairy cell leukemia/lymphoma of the breast: a case report and review of the literature.	BRAF
25239585	10.1016/j.rmr.2013.11.004	2014	[An unusual mediastinal mass].	BRAF
25288236	10.1016/j.humpath.2014.08.005	2014	Molecular alterations in non-small cell lung carcinomas of the young.	BRAF
25302162	10.5306/wjco.v5.i4.576	2014	Review of the current targeted therapies for non-small-cell lung cancer.	BRAF
23009221	10.3109/10428194.2012.733878	2013	BRAF V600E mutation in adult acute lymphoblastic leukemia.	BRAF
23088640	10.3109/10428194.2012.742525	2013	BRAF mutations in chronic lymphocytic leukemia.	BRAF
23235345	10.1097/PAI.0b013e3182688e59	2013	Lack of BRAF V600E protein expression in primary central nervous system lymphoma.	BRAF
23349307	10.3324/haematol.2012.078071	2013	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.	BRAF
23401445	10.1200/JCO.2012.42.9829	2013	New targetable oncogenes in non-small-cell lung cancer.	BRAF
23696960	10.5306/wjco.v4.i2.29	2013	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.	BRAF
23708073	10.1097/PPO.0b013e318297216a	2013	Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.	BRAF
23751074	10.1111/pcmr.12129	2013	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.	BRAF
23759932	10.1097/PAS.0b013e318283099f	2013	Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation.	BRAF
23841470	10.1164/rccm.201305-0843PP	2013	The impact of genomic changes on treatment of lung cancer.	BRAF
23885909	10.1016/j.jvir.2013.04.019	2013	Personalized oncology in interventional radiology.	BRAF
23923114	10.4103/1947-2714.114172	2013	Langerhans Cell Sarcoma Arising from Chronic Lymphocytic Lymphoma/Small Lymphocytic Leukemia: Lineage Analysis and BRAF V600E Mutation Study.	BRAF
23923507	10.1182/blood-2012-12-473181	2013	Collision of chronic lymphocytic leukemia/small lymphocytic lymphoma and melanoma.	BRAF
23930754	10.1517/14712598.2013.827657	2013	Targeted therapy for NSCLC with driver mutations.	BRAF
24041576	10.1182/blood-2013-08-460311	2013	Genome sequencing of lymphoid malignancies.	BRAF
24103785	10.1684/bdc.2013.1823	2013	[Molecular and therapeutic advances in Hairy cell leukemia].	BRAF
24159168	10.1182/blood-2013-07-513523	2013	BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia.	BRAF
24206589	10.1016/j.pharma.2013.07.001	2013	[Characterization of principal predictive biomarkers of targeted therapies in thoracic cancer].	BRAF
24342286	10.1053/j.semdp.2013.11.007	2013	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.	BRAF
22028477	10.1182/blood-2011-08-371179	2012	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.	BRAF
22072557	10.1182/blood-2011-08-368209	2012	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.	BRAF
22072743	10.1210/jc.2011-0484	2012	BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.	BRAF
22133769	10.3324/haematol.2011.054874	2012	Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders.	BRAF
22246856	10.1002/hon.1023	2012	Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia.	BRAF
22317764	10.1158/1078-0432.CCR-11-2511	2012	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	BRAF
22339435	10.3109/10428194.2012.668188	2012	Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms.	BRAF
22531170	10.1097/PAS.0b013e3182549b50	2012	Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.	BRAF
22639828	10.3109/10428194.2012.695777	2012	Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.	BRAF
23161722	10.1309/AJCP5TWORA0TMXGL	2012	Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders.	BRAF
21625473	10.1371/journal.pone.0019861	2011	A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.	BRAF
21663470	10.1056/NEJMoa1014209	2011	BRAF mutations in hairy-cell leukemia.	BRAF
19626635	10.1002/hed.21178	2010	Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.	BRAF
19551857	10.1002/ijc.24681	2009	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.	BRAF
17483702	10.1097/MPH.0b013e3180547136	2007	Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.	BRAF
17525723	10.1038/sj.leu.2404761	2007	The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene.	BRAF
15538400	10.1038/sj.leu.2403589	2005	Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.	BRAF
15705790	10.1182/blood-2004-09-3683	2005	B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells.	BRAF
15191558	10.1111/j.0022-202X.2004.22722.x	2004	BRAF point mutations in primary melanoma show different prevalences by subtype.	BRAF
14612909	10.1038/sj.bjc.6601371	2003	BRAF mutations in non-Hodgkin's lymphoma.	BRAF
